The rise of Sildenafil initially drove a period of growth for major pharmaceutical companies, but recent changes present a complicated picture for those considering a stake. Generic versions are reducing more info revenue, and ongoing litigation add further complexity to the equation. While some companies may still see gains from adjacent offerings